MedTrace Logo

Cofrogliptin and Linagliptin as add-on Therapy to Insulin in Type 2 Diabetes

NCT07198932 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 594

Last updated 2025-09-30

No results posted yet for this study

Summary

This study is a multicenter, prospective, non-interventional real-world study to evaluate the clinical outcomes of biweekly cofrogliptin versus daily linagliptin as an add-on therapy in Chinese adult T2D patients.

Conditions

Interventions

DRUG

Cofrogliptin add to insulin

Patients will be treated with commercially available cofrogliptin according to routine clinical practice at the discretion of the treating physician.

DRUG

Linagliptin add to insulin

Patients will be treated with commercially available linagliptin according to routine clinical practice at the discretion of the treating physician.

Sponsors & Collaborators

  • Yanbing Li

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2027-07-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07198932 on ClinicalTrials.gov